 Growth-inhibitory factor obtained from human brain |
| What is claimed is: 1. A pure protein having a growth-inhibitory activity extracted from the human ... |
|
| Substituted aminopyrimidines as antihypertensives |
| What is claimed is: 1. A compound having the formula: ##STR16## wherein R.sup.1 is alkyl of 1-6 ... |
|
| 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
| What is claimed is: 1. A compound having the formula ##STR34## wherein ##STR35## with the proviso ... |
|
| Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
| OF THE INVENTION The starting heterocyclic intermediates of the formula ##STR18## are prepared ... |
|
| Oxazolidinedione hypoglycemic agents |
| OF THE INVENTION The compounds of formula I wherein the dotted line represents no bond are ... |
|
| Imidazoline derivatives, salts thereof and their use as pesticides |
| What is claimed is: 1. An imidazoline compound of formula (I): ##STR16## wherein Ar is selected ... |
|
| Pesticidal anilinomethylimidazolines |
| We claim: 1. A method for preventing pests of the Order Acarina from producing viable eggs which ... |
|
| Amidines, preparation process and therapeutical application thereof |
| We claim: 1. Compounds of the formula: ##STR35## in which: R.sub.1 and R.sub.2 represent each a ... |
|
| 3-aryloxy-3-substituted propanamines |
| OF THE INVENTION In the above formula, the term C.sub.1 -C.sub.4 alkyl represents a straight or ... |
|
| Use of .alpha..sub.1C specific compounds to treat benign prostatic hyperlasia |
| OF THE INVENTION The present invention provides a method of treating benign prostatic hyperplasia ... |
|
|
Sodium bicarbonate dialysate
| Details |
Inventors: Itoh, Nobuo;
Assignee: Nikkiso Co., Ltd. (Tokyo, JP); Towa Pharmaceutical Co., Ltd. (Kadoma, JP)
Primary Examiner: Spear; Frank
Assistant Examiner:
Attorney, Agent or Firm: Oblon, Spivak, McClelland, Maier & Neustadt
A sodium bicarbonate dialysate comprising an electrolyte granule A composed mainly of sodium chloride and containing no sodium bicarbonate and an electrolyte granule B containing sodium bicarbonate, wherein the granule B is granules of sodium bicarbonate primary particles having a particle size of at most 250 .mu.m, and the particle size of the secondary particles after granulation is from 0.1 to 10 mm. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A sodium bicarbonate dialysate comprising an electrolyte composition A composed mainly of sodium chloride and containing no sodium bicarbonate and an electrolyte granule B containing sodium bicarbonate, wherein the granule B is granules of sodium bicarbonate primary particles having a particle size of at most 250 .
mu.
m, and the particle size of he secondary particles after granulation is from 0.
1 to 10 mm.
2.
The dialysate according to claim 1, wherein the granulation of the granule B is carried out by adding water to a powder of its components so that the water content is from 0.
5 to 25% by weight, followed by mixing, granulation and drying.
3.
The dialysate according to claim 1 or 2, wherein the granule B is granules of a mixture comprising sodium bicarbonate and from 1 to 75% by weight, based on the weight of the entire granule B, of sodium chloride.
4.
The dialysate according to claim 1 or 2, wherein the granule B is granules of a mixture comprising sodium bicarbonate and from 0.
3 to 30% by weight, based on the weight of the entire granule B, of sodium acetate.
5.
The dialysate according to claim 3, wherein the granule B contains from 1 to 5% by weight of sodium chloride.
6.
The dialysate according to claim 1 or 2, wherein the solubilization time of the granule B is at most 2 times that of the sodium bicarbonate primary particles.
7.
The dialysate according to claim 1 or 2, wherein the composition A is in the form of granules.
8.
The dialysate according to claim 7, wherein the angle of repose of the granule A or the granule B is at most 55.
degree.
.
9.
The dialysate according to claim 7, wherein the apparent specific gravity of the granule A or the granule B is from 0.
5 to 0.
9 as an aerated bulk density and from 0.
6 to 1.
1 as a packed bulk density.
10.
The dialysate according to claim 7, wherein the pore volume of the granule A or the granule B is from 0.
05 to 1.
0 cc/g.
11.
The dialysate according to claim 7, wherein the granule A and he granule B are mixed after granulation
|
| Related patents |
|
|
Dry dialysate composition
The problems described above are solved by an automated hemodialysis-filtration system comprising a supply-regulated blood pump, a hemofilter, a hemodialyzer, and an ...
|
|
|
Device for the preparation of a solution for medical use
OF THE PREFERRED EMBODIMENTS This installation is organized around a device consisting of a set of five cartridges, respectively referenced 1 to 5, arranged in parallel ...
|
|
|
Method of producing an artificial kidney perfusion component for bicarbonate dialysis and the artificial kidney perfusion component
After an intensive research undertaken to overcome the above-mentioned disadvantages of the prior arts, the inventor of the present invention discovered that ...
|
|
|
Pharmaceutical preparations containing platinum complexes/phosphonic acid liquid and processes for their use
What is claimed is: 1. A pharmaceutical preparation comprising at least 0.5% by weight of a pharmaceutical vehicle and also comprising a platinum complex or a salt, with ...
|
|
|
Cephalosporin analogues and antimicrobial compositions
What we claim is: 1. The syn isomer of a compound of the formula: ##STR20## wherein R.sup.3 is furyl; A is lower alkoxyiminomethylene; R.sup.2 is carboxy; and ...
|
|
|
Aqueous protein solutions stable to denaturation
What is claimed is: 1. A sterile aqueous solution of a water soluble biologically active protein, which solution has a pH between 6.8 and 8 and additionally has admixed ...
|
|
|
Cyclic analogs of atrial natriuretic peptides
We claim: 1. A peptide compound having natriuretic, diuretic and/or vasodilator activity in mammals, which has the formula: X.sub.1 A.sub.y X.sub.2 -AA.sub.8 -AA.sub.9 -A...
|
|
|
Method for inhibiting blood vessel blockage using octapeptide compositions
In general, the present invention is directed to a method of inhibiting blood vessel blockage in a mammal, e.g., a human, by administering to a patient a therapeutically ...
|
|
|
Novel treatment for acute organic cerebral syndromes (strokes)
I claim: 1. A method for treating individuals suffering from the acute phases of the organic cerebral syndrome due to arterial occlusion which comprises administering to ...
|
|
|
Novel naphthalene derivative
What we claim is: 1. A naphthalene derivative of the formula: ##STR55## wherein Ring A is an unsubstituted benzene ring, a benzene ring having 1 -3 substituent(s) ...
|
|
|
Vasodialators 
